Concurrent, Prolonged Use of Bedaquiline and Delamanid for Multidrug-Resistant Tuberculosis
10.3904/kjm.2019.94.3.294
- Author:
Dong Gon HYUN
1
;
Se Hee LEE
;
Kyung Wook JO
;
Tae Sun SHIM
Author Information
1. Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. shimts@amc.seoul.kr
- Publication Type:Clinical Trial
- Keywords:
Bedaquiline;
Delamanid;
Tuberculosis;
Multidrug-resistant
- MeSH:
Humans;
Korea;
Tuberculosis;
Tuberculosis, Multidrug-Resistant
- From:Korean Journal of Medicine
2019;94(3):294-298
- CountryRepublic of Korea
- Language:English
-
Abstract:
Bedaquiline and delamanid were recently approved for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Korea. A treatment duration of 24 weeks was established based on phase 2 clinical trial data, although the combined use of these two drugs is typically not recommended because it may exaggerate QT prolongation. Here, we present a case of prolonged treatment (48 weeks) with a combination of bedaquiline and delamanid for pulmonary MDR-TB. The patient had previously been diagnosed with extensively drug-resistant TB but had been left untreated for the past 9 years due to a shortage of effective drugs. A combination of bedaquiline and delamanid successfully treated MDR-TB, highlighting the potential efficacy of these drugs for patients with drug-resistant TB infections.
